Loading today’s stories
Science3 distinct publishers3 min readUpdated
Osaka researchers found CD4 cytotoxic T lymphocytes rise from 4 percent to 17.6 percent of circulating T cells across the oldest age brackets. Outside immunologists want function, not just counts.
The Scientist · Science desk
Compiled by The ScientistSomething wrong?How this is made
A team at the University of Osaka reported in Cell Reports that a rare hybrid immune cell, the CD4 cytotoxic T lymphocyte, takes up a progressively larger share of circulating T cells in the very old, reaching a median of 17.6 percent in people aged 110 and over [1][2]. That cuts against the default model of immune aging as subtraction, in which the system loses its capacity to clear pathogens and abnormal cells such as precancerous or senescent ones [17].
CD4 CTLs sit awkwardly in textbook immunology. T cells are conventionally split into helpers that coordinate a response and killers that destroy infected or malignant cells; CD4 CTLs do both, and they are uncommon in most people [21][12]. The same group flagged them as a hallmark of supercentenarians in 2019 [11]. The new work tries to quantify the trajectory.
The cohort is 28 people: eight aged 70 to 99, ten centenarians, and ten supercentenarians [3]. Median CD4 CTL share of total T cells was 4 percent, 9.6 percent, and 17.6 percent across those brackets [2], a 4.4-fold spread between the youngest and oldest groups [20]. The team ran integrated single-cell profiling combining transcriptome, surface protein, and T cell receptor sequence data [5] on more than 40,000 T cells [4], then applied a machine-learning model to a larger dataset of 1,500 people of all ages, which showed a similar trend [6].
Two details do more work than the percentages. First, participants with higher CD4 CTL levels carried many cellular clones, which the authors read as evidence the cells are responding to something rather than merely accumulating [7]. Second, the cells showed no signs of T cell exhaustion, the loss of killing capacity that usually accompanies chronic stimulation [8]. The authors conclude the population expands and diversifies as an adaptation to persistent antigens, potentially contributing to longevity through cancer suppression [9]. Hashimoto's framing is that immune aging is not simply decline, and that selective expansion of certain T cells suggests continued adaptation even in extreme old age [10].
The obvious limit is n. Ten supercentenarians is thin by any normal standard, though Hashimoto notes Japan's national census counts only about 150 in the country, making ten a substantial fraction [13] - roughly 7 percent of the national total [22]. The other limit is direction of causation. Rahul Sharma, an immunologist at the University of Virginia who was not involved, called the study commendable but said more work is needed, and raised the possibility that the cells are simply adapting to survive in older people without benefiting the host [14]. Alon Monsonego at Ben-Gurion University of the Negev, also uninvolved, said the work is not a breakthrough but could serve as a starting point [15]. Manel Esteller at the Sant Pau Research Institute, who studied María Branyas Morera before her death in 2024 at 117 years and 168 days, said the findings show supercentenarians are enriched in cells that attack threats and probably cancer cells [16].
What to watch: whether anyone identifies what these cells actually target. Hashimoto says the next questions are the specific antigens and the role of CD4 CTLs in younger people, some of whom also carry large numbers [19]. Until a target is named, expansion plus clonality plus absent exhaustion is a strong correlation and nothing more.
Follow any of these and your For You feed starts watching them — no settings page required.
Ranked by verification strength, evidence, and original report placement.
The proportion of CD4 cytotoxic T lymphocytes increased with age, with median percentages of 4%, 9.6%, and 17.6% in the 70-99, 100-109, and 110-and-older groups respectively.
In 2019 the same team of genetics researchers found that supercentenarians, people who live beyond age 110, have an unusually high amount of CD4 CTLs; the team describes CD4 CTLs as a hallmark of supercentenarians identified in their previous study.
The new study examined 28 people in three age groups: eight people aged 70 through 99, 10 centenarians, and 10 supercentenarians.
The investigators conducted integrated single-cell profiling of T cells, combining transcriptome, surface protein, and TCR sequence data across age groups including rare cohorts of centenarians and supercentenarians.
The researchers analyzed more than 40,000 immune system T cells.
A team at the University of Osaka published a paper in Cell Reports titled "CD4 CTLs in supercentenarians: Signs of adaptive expansion in healthy aging," with Kosuke Hashimoto, an associate professor at the University of Osaka, as first author.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Peer-reviewed multi-omic profiling on a very small cohort
The finding rests on a published Cell Reports paper with integrated single-cell transcriptome, surface-protein and TCR data over 40,000-plus T cells, a consistent monotonic gradient (4% / 9.6% / 17.6% medians) reported identically by three outlets, a clonality signal, and a machine-learning check on 1,500 people. It is capped by n=28 with 10 supercentenarians, a cross-sectional design, no functional killing assay behind the 'no exhaustion' result, unknown antigen targets, and a within-cohort outlier under 100 with the highest CD4 CTL share.
Publication only, no uptake to measure
The only observable event in the cluster is the paper's publication. No sources describe replication by other groups, clinical trials, diagnostics, therapeutic programmes, funding or any downstream use of the finding, so there is no adoption surface to score; scoring it would require inferring facts the sources do not supply.
Headlines assert cancer protection the data only hypothesises
Publisher framing runs ahead of what was measured. Headlines and ledes promise immune systems 'that fight off cancer', a 'secret weapon' and a 'cellular superpower', while the underlying result is a correlation in cell frequency plus clonality in 28 people, with the causal step to longevity or cancer suppression flagged as a hypothesis by the authors themselves and rejected as a breakthrough by two uninvolved CD4 CTL researchers, one of whom says the cells may confer no benefit at all. The gap is presentational rather than fabricated: the numbers are reported accurately and the researcher quotes are hedged.
Team extending its own 2019 hallmark claim; no commercial stake shown
The main directional pressure is scientific self-continuity: the same group that named CD4 CTLs a hallmark of supercentenarians in 2019 is now quantifying and interpreting that same marker, with Hashimoto lead author of both papers, and GEN's account runs entirely on institutional quotes with no outside voice. Offsetting this, no company, funder, patent or product interest appears anywhere in the cluster, and one member published two uninvolved researchers who push back. Absent disclosure of funding or competing interests, this is scored as moderate-low rather than clean.
Facts firm, interpretation open
Confidence is high on the descriptive layer — a named journal paper, an explicit title and first author, and a numeric gradient reproduced consistently across three independent outlets — and lower on causation, where the cluster itself is split between the authors' adaptive-immunosurveillance reading and two specialists who say function is unknown. Single-source items (the 1,500-person machine-learning check, the census framing, the clone-share percentages) and the mid-quote truncation of the GEN piece hold the score below the descriptive layer's reliability.
science
Myelin repair cells make their own stress hormone, and it seems to set the clock1 distinct publisher
Distinct publishers with included, body-backed reporting in this cluster.
1 article · August 19, 2026
1 article · August 19, 2026
1 article · August 19, 2026